BACKGROUND: Data support the role of interferon (IFN)gamma and interleukin (IL)12 in perinatal complications. IFNgamma T(+874)A and IL12 p40 promoter CTCTAA/GC polymorphisms may have an effect on cytokine production. METHODS: DNA was extracted from dried blood samples of 153 low birthweight (LBW) infants and 172 healthy term infants. IFNgamma and IL12 genetic polymorphisms were determined to investigate the association between polymorphisms and ventilation characteristics, bronchopulmonary dysplasia (BPD) and other perinatal disorders. RESULTS: The IFNgamma(+874)A allele was over-represented in LBW infants. Carriers of the IFNgamma(+874)T allele required mechanical ventilation and oxygen supplementation for time periods 41% and 35%, respectively, shorter than those required by those not carrying the IFNgamma(+874)T allele. Stepwise logistic regression analysis showed that carriers of the IFNgamma(+874)T allele were protected against BPD (odds ratio (OR) 0.35 (95% confidence interval (CI) (0.12 to 0.99))) and patent ductus arteriosus (OR 0.43 (95% CI 0.19 to 0.97)), whereas carriers of the IFNgamma(+874)A allele were at higher risk of severe hypotension (OR 3.40 (95% CI 1.01 to 11.52)) and respiratory distress syndrome (OR 4.03 (95% CI 1.30 to 12.50)). Carriers of the IL12 GC allele were protected against pneumonia (OR 0.32 (95% CI 0.14 to 0.75)). Carriers of the IL12 CTCTAA allele were at higher risk of developing necrotising enterocolitis (NEC; OR 2.37 (95% CI 1.01 to 5.53)). CONCLUSIONS: Carrier state of the IFNgamma(+874)A allele presents an increased risk for premature birth and lung damage, as well as other perinatal complications. The risks of pneumonia and NEC are higher in heterozygotic carriers of the IL12 CTCTAA/GC polymorphism. Further studies are needed to determine whether these associations are the result of altered cytokine-producing capacity in infants carrying the tested alleles.
BACKGROUND: Data support the role of interferon (IFN)gamma and interleukin (IL)12 in perinatal complications. IFNgamma T(+874)A and IL12 p40 promoter CTCTAA/GC polymorphisms may have an effect on cytokine production. METHODS: DNA was extracted from dried blood samples of 153 low birthweight (LBW) infants and 172 healthy term infants. IFNgamma and IL12 genetic polymorphisms were determined to investigate the association between polymorphisms and ventilation characteristics, bronchopulmonary dysplasia (BPD) and other perinatal disorders. RESULTS: The IFNgamma(+874)A allele was over-represented in LBW infants. Carriers of the IFNgamma(+874)T allele required mechanical ventilation and oxygen supplementation for time periods 41% and 35%, respectively, shorter than those required by those not carrying the IFNgamma(+874)T allele. Stepwise logistic regression analysis showed that carriers of the IFNgamma(+874)T allele were protected against BPD (odds ratio (OR) 0.35 (95% confidence interval (CI) (0.12 to 0.99))) and patent ductus arteriosus (OR 0.43 (95% CI 0.19 to 0.97)), whereas carriers of the IFNgamma(+874)A allele were at higher risk of severe hypotension (OR 3.40 (95% CI 1.01 to 11.52)) and respiratory distress syndrome (OR 4.03 (95% CI 1.30 to 12.50)). Carriers of the IL12 GC allele were protected against pneumonia (OR 0.32 (95% CI 0.14 to 0.75)). Carriers of the IL12 CTCTAA allele were at higher risk of developing necrotising enterocolitis (NEC; OR 2.37 (95% CI 1.01 to 5.53)). CONCLUSIONS: Carrier state of the IFNgamma(+874)A allele presents an increased risk for premature birth and lung damage, as well as other perinatal complications. The risks of pneumonia and NEC are higher in heterozygotic carriers of the IL12 CTCTAA/GC polymorphism. Further studies are needed to determine whether these associations are the result of altered cytokine-producing capacity in infants carrying the tested alleles.
Authors: G Morahan; C S Boutlis; D Huang; A Pain; J R Saunders; M R Hobbs; D L Granger; J B Weinberg; N Peshu; E D Mwaikambo; K Marsh; D J Roberts; N M Anstey Journal: Genes Immun Date: 2002-11 Impact factor: 2.676
Authors: Grant Morahan; Dexing Huang; Mark Wu; Barbara J Holt; Gregory P White; Garth E Kendall; Peter D Sly; Patrick G Holt Journal: Lancet Date: 2002-08-10 Impact factor: 79.321
Authors: András Treszl; István Kocsis; Miklós Szathmári; Agnes Schuler; Erika Héninger; Tivadar Tulassay; Barna Vásárhelyi Journal: Biol Neonate Date: 2003
Authors: Michiel C Warlé; Ayar Farhan; Herold J Metselaar; Wim C J Hop; Chris Perrey; Pieter E Zondervan; Marcel Kap; Jaap Kwekkeboom; Jan N M Ijzermans; Hugo W Tilanus; Vera Pravica; Ian V Hutchinson; Gerda J Bouma Journal: Liver Transpl Date: 2003-02 Impact factor: 5.799
Authors: Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese Journal: Semin Fetal Neonatal Med Date: 2018-02-24 Impact factor: 3.926
Authors: Nahid Waleh; Ryan Hodnick; Nami Jhaveri; Suzanne McConaghy; John Dagle; Steven Seidner; Donald McCurnin; Jeffrey C Murray; Robin Ohls; Ronald I Clyman Journal: Pediatr Res Date: 2010-10 Impact factor: 3.756
Authors: Megan M Vucovich; Robert B Cotton; Elaine L Shelton; Jeremy A Goettel; Noah J Ehinger; Stanley D Poole; Naoko Brown; James L Wynn; Bibhash C Paria; James C Slaughter; Reese H Clark; Mario A Rojas; Jeff Reese Journal: Am J Physiol Heart Circ Physiol Date: 2014-07-03 Impact factor: 4.733